Biogen stops testing Tysabri to treat stroke after study fails
(Reuters) - Biogen Inc said on Wednesday it would stop developing its multiple sclerosis drug Tysabri to treat patients with acute ischemic stroke after it failed a mid-stage study. (Source: Reuters: Health)
Source: Reuters: Health - February 7, 2018 Category: Consumer Health News Tags: healthNews Source Type: news
Biogen stops developing Tysabri to treat stroke after failed study
(Reuters) - Biogen Inc said on Wednesday it would stop developing Tysabri to treat acute ischemic stroke patients after the drug failed to meet the main goal of a mid-stage study. (Source: Reuters: Health)
Source: Reuters: Health - February 7, 2018 Category: Consumer Health News Tags: healthNews Source Type: news
Less Frequent Natalizumab Dosing Dramatically Reduces PML Risk Less Frequent Natalizumab Dosing Dramatically Reduces PML Risk
Extended-interval dosing of natalizumab was associated with a 94% lower risk for progressive multifocal leukoencephalopathy vs standard dosing in patients with MS positive for anti-JC virus antibody.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 3, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
Extending dosing intervals reduces deadly side effect risk from multiple sclerosis drug
(NYU Langone Health / NYU School of Medicine) A commonly-prescribed multiple sclerosis (MS) infusion medication, natalizumab, linked to a rare but serious side effect is safer to use when dosing intervals are extended, according to a new study led by MS specialists at NYU Langone Health. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 2, 2018 Category: International Medicine & Public Health Source Type: news
Rituximab Outperforms Other Drugs in RRMS Rituximab Outperforms Other Drugs in RRMS
In a new study, rituximab was superior to other drugs -- including fingolimod, natalizumab, and dimethyl fumarate -- in efficacy, safety, and tolerability in patients with relapsing-remitting MS.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 11, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
Dimethyl Fumarate: A Possible Exit Strategy From Natalizumab Dimethyl Fumarate: A Possible Exit Strategy From Natalizumab
Is dimethyl fumarate effective in preventing disease rebound after natalizumab discontinuation in patients with MS?Journal of Neurology, Neurosurgery, and Psychiatry (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 22, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news
FDA Drug Safety Communication: New risk factor for Progressive Multifocal Leukoencephalopathy (PML) associated with Tysabri (natalizumab)
[01-20-2012] The U.S. Food and Drug Administration (FDA) is informing the public that testing positive for anti-JC virus (JCV) antibodies has been identified as a risk factor for progressive multifocal leukoencephalopathy (PML). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 11, 2017 Category: Drugs & Pharmacology Source Type: news
Natalizumab Beneficial in Secondary Progressive MS? Natalizumab Beneficial in Secondary Progressive MS?
A new post hoc analysis of the ASCEND trial in secondary progressive multiple sclerosis suggests that natalizumab is effective in this population, particularly for upper limb function.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 21, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
PML Reported in Patient Receiving Ocrelizumab PML Reported in Patient Receiving Ocrelizumab
But the case could be attributable to ' carryover ' from the patient ' s previous treatment with natalizumab, the company said.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 25, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
Genentech Reports PML Case with Ocrelizumab
(MedPage Today) -- Occurred in patient transitioning from natalizumab (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - May 24, 2017 Category: Primary Care Source Type: news
Enhanced Atypical Lymphocytes in Natalizumab - Treated MS
Enhanced fraction of atypical lymphocytes, especially binucleated and plasmacytoid lymphocytes (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - May 24, 2017 Category: Cancer & Oncology Tags: Internal Medicine, Neurology, Oncology, Pathology, Pharmacy, Journal, Source Type: news
March's top stories: Perrigo's $2.85bn sale, Cancer Research UK's Precision Panc project
Perrigo completed the sale of Tysabri drug royalty to RPI for $2.85bn, London's Institute of Cancer Research (ICR) revealed new secrets about the genetic causes of cancer, and Eli Lilly acquired CoLucid Pharmaceuticals for $960m. Pharmaceutical-techn … (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - April 2, 2017 Category: Pharmaceuticals Source Type: news
Perrigo completes sale of Tysabri drug royalty to RPI for $2.85bn
Drug manufacturer Perrigo has completed the sale of its right to the royalty stream from the global net sales of the drug Tysabri (natalizumab) to Royalty Pharma's (RPI) affiliate RPI Finance Trust for $2.85bn. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - March 27, 2017 Category: Pharmaceuticals Source Type: news
Perrigo to sell Tysabri drug royalty to RPI for $2.85bn
Ireland-based Perrigo has signed an agreement to sell its right to the royalty stream from the global net sales of the multiple sclerosis drug Tysabri (natalizumab) to Royalty Pharma ’s (RPI) affiliate RPI Finance Trust for $2.85bn. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - March 1, 2017 Category: Pharmaceuticals Source Type: news
Federal investigators subpoena Biogen over MS drug prices
Biogen (NSDQ:BIIB) said on Thursday that it received a subpoena in December last year from federal investigators about the prices of its top-selling multiple sclerosis drugs, Tecfidera, Avonex, Tysabri and Plegridy.
In its annual regulatory filing, the company wrote that the investigators inquired about “government price reporting, rebate payments and Biogen’s co-pay assistance programs.” While Cambridge, Mass.-based Biogen said it was cooperating with the federal probe, it did not provide any other specific details.
Get the full story at our sister site, Drug Delivery Business News.
The post Federal ...
Source: Mass Device - February 3, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Legal News Neurological Pharmaceuticals Wall Street Beat Biogen Source Type: news
